Carvedilol for Heart Failure
Carvedilol (Coreg - SmithKline Beecham and Boehringer-Mannheim), a betaadrenergic and alpha-adrenergic blocker approved by the FDA for treatment of hypertension in 1995, but not marketed at that time, has now been approved and marketed for treatment of mild or moderate (NYHA class II or III) heart failure stabilized on other drugs. It is being promoted as an add-on drug that reduces the morbidity and mortality of the disease....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Carvedilol for Heart Failure
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1010
Article Code: 1010a
Date: September 26, 1997
Volume: 39
Pages: 89-91
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1010
Article Code: 1010a
Date: September 26, 1997
Volume: 39
Pages: 89-91
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)